These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34893821)

  • 21. Risks and outcomes of invasive fungal infections in pediatric allogeneic hematopoietic stem cell transplant recipients receiving fluconazole prophylaxis: a multicenter cohort study by the Turkish Pediatric Bone Marrow Transplantation Study Group.
    Hazar V; Karasu GT; Uygun V; Öztürk G; Kiliç SÇ; Küpesiz A; Daloglu H; Aksoylar S; Atay D; Ince EÜ; Karakükçü M; Özbek N; Tayfun F; Kansoy S; Özyürek E; Akçay A; Gürsel O; Haskologlu S; Kaya Z; Yilmaz S; Tanyeli A; Yesilipek A
    Med Mycol; 2019 Feb; 57(2):161-170. PubMed ID: 29608706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents.
    Kim GYG; Burns J; Freyer CW; Hamilton KW; Frey NV; Gill SI; Hexner EO; Luger SM; Mangan JK; Martin ME; McCurdy SR; Perl AE; Porter DL; Schuster MG; Stadtmauer EA; Loren AW
    Am J Hematol; 2020 Jul; 95(7):792-798. PubMed ID: 32242967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and outcome of systemic fungal infections in renal transplant recipients - A tertiary care experience.
    Shekar M; Elumalai R; Elayaperumal I; Yelahanka RP; Anandkumar DG; Bandi VK; Matcha J
    Saudi J Kidney Dis Transpl; 2019; 30(5):1137-1143. PubMed ID: 31696853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
    Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
    Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distribution of invasive fungal infections: Molecular epidemiology, etiology, clinical conditions, diagnosis and risk factors: A 3-year experience with 490 patients under intensive care.
    Borjian Boroujeni Z; Shamsaei S; Yarahmadi M; Getso MI; Salimi Khorashad A; Haghighi L; Raissi V; Zareei M; Saleh Mohammadzade A; Moqarabzadeh V; Soleimani A; Raeisi F; Mohseni M; Mohseni MS; Raiesi O
    Microb Pathog; 2021 Mar; 152():104616. PubMed ID: 33212195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on invasive fungal infections in the Middle Eastern and North African region.
    Osman M; Al Bikai A; Rafei R; Mallat H; Dabboussi F; Hamze M
    Braz J Microbiol; 2020 Dec; 51(4):1771-1789. PubMed ID: 32623654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk Factors and Outcomes of Invasive Fungal Infections in Allogeneic Hematopoietic Cell Transplant Recipients.
    Miceli MH; Churay T; Braun T; Kauffman CA; Couriel DR
    Mycopathologia; 2017 Jun; 182(5-6):495-504. PubMed ID: 28124219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Changing Epidemiology of Invasive Fungal Infections.
    Enoch DA; Yang H; Aliyu SH; Micallef C
    Methods Mol Biol; 2017; 1508():17-65. PubMed ID: 27837497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fungal infections in hematopoietic stem cell transplantation in children at a pediatric children's hospital in Argentina.
    Gomez SM; Caniza M; Fynn A; Vescina C; Ruiz CD; Iglesias D; Sosa F; Sung L
    Transpl Infect Dis; 2018 Aug; 20(4):e12913. PubMed ID: 29679436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology and treatment approaches in management of invasive fungal infections in hematological malignancies: Results from a single-centre study.
    Fracchiolla NS; Sciumè M; Orofino N; Guidotti F; Grancini A; Cavalca F; Freyrie A; Goldaniga MC; Consonni D; Mattiello V; Pettine L; Cortelezzi A
    PLoS One; 2019; 14(5):e0216715. PubMed ID: 31071175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions.
    Cho HJ; Baek DW; Kim J; Lee JM; Moon JH; Sohn SK
    Expert Rev Hematol; 2021 Sep; 14(9):819-830. PubMed ID: 34375536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections.
    Furuno JP; Tallman GB; Noble BN; Bubalo JS; Forrest GN; Lewis JS; Bienvenida AF; Holmes CA; Weber BR; McGregor JC
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
    Brochard J; Morio F; Mahe J; Le Pape P; Guimard T; Mahe B; Leterrier M; Morrier M; Raffi F; Boutoille D
    Med Mal Infect; 2020 Nov; 50(8):742-745. PubMed ID: 32777360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiology and outcome of invasive fungal infections and methicillin-resistant Staphylococcus aureus (MRSA) pneumonia and complicated skin and soft tissue infections (cSSTI) in Lebanon and Saudi Arabia.
    Moghnieh R; Alothman AF; Althaqafi AO; Matar MJ; Alenazi TH; Farahat F; Corman SL; Solem CT; Raghubir N; Macahilig C; Stephens JM
    J Infect Public Health; 2017; 10(6):849-854. PubMed ID: 28487208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk Factors Associated With Invasive Fungal Infections in Kidney Transplant Patients.
    Leitheiser S; Harner A; Waller JL; Turrentine J; Baer S; Kheda M; Nahman NS; Colombo RE
    Am J Med Sci; 2020 Feb; 359(2):108-116. PubMed ID: 31836132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical Characteristics and Risk Factors of Invasive Fungal Infections in Acute Leukemia Patients in Tropical Regions].
    Zheng WS; Guan LX; Wang SY; Hu YL; Peng B; Bo J; Wang QS; Gao XN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):99-106. PubMed ID: 35123610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia.
    Fiorcari S; Maffei R; Vallerini D; Scarfò L; Barozzi P; Maccaferri M; Potenza L; Ghia P; Luppi M; Marasca R
    Front Immunol; 2020; 11():2158. PubMed ID: 32983178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Classification performance of administrative coding data for detection of invasive fungal infection in paediatric cancer patients.
    Valentine JC; Worth LJ; Verspoor KM; Hall L; Yeoh DK; Thursky KA; Clark JE; Haeusler GM
    PLoS One; 2020; 15(9):e0238889. PubMed ID: 32903280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ibrutinib-associated cutaneous mucormycosis due to an
    Nguyen TM; Amenta E; Chapman L; Yellapragada S; Krishnan B; Lim J; Hamill RJ
    Ther Adv Infect Dis; 2024; 11():20499361241241199. PubMed ID: 38545450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.